• Genentech released new 12-month and 6-month real-world VOYAGER study results for Vabysmo at EURETINA 2026.
• Data showed vision outcomes held up in routine care across wet AMD, diabetic macular edema, and retinal vein occlusion.
• Anatomical measures improved broadly in both treatment-naïve patients and those switched from prior therapies, supporting durability in practice.
• Safety matched the established profile from earlier late-stage trials, with no new safety signals flagged in the dataset.
• VOYAGER enrolled more than 5,000 patients, positioning the evidence base as a key support for standard-of-care use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genentech Inc. published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.